Fundación Instituto de Inmunología de Colombia (FIDIC), Bogotá, Colombia. marina
J Virol Methods. 2012 Oct;185(1):32-8. doi: 10.1016/j.jviromet.2012.05.023. Epub 2012 Jun 1.
Cervical samples were evaluated for human papillomavirus (HPV) presence using the hybrid capture-2 (HC2) assay and the polymerase chain reaction (PCR) with three different primer sets (GP5+/6+, MY09/11 and pU1M/2R). PCR results were compared to HC2 and results of all assays were compared to cytological and colposcopy findings. Post-test probability was assessed in individual assays and test combinations. HPV-DNA prevalence was 36.5% with HC2 and 55.2% with PCR. MY09/11 detected HPV-DNA in 38% of samples, GP5+/6+ in 19.1% and pU1M/2R in 16.4%. pU1M/2R and HC2 had the highest concordance (75.31%, k=0.39 in the whole population; 74.1%, k=0.5 in women with abnormal cytology). pU1M/2R had the best diagnostic performance, including optimal post-test probabilities and cervical abnormality detection (individually or in a panel of tests). Women positive for pU1M/2R may be at higher risk of disease progression; the assay performance when combined with a Pap smear in cervical cancer screening programs should be evaluated.
采用杂交捕获-2 （HC2）检测法和聚合酶链反应（PCR）联合三种不同引物组（GP5+/6+、MY09/11 和 pU1M/2R）对宫颈标本进行人乳头瘤病毒（HPV）检测。将 PCR 结果与 HC2 进行比较，并将所有检测结果与细胞学和阴道镜检查结果进行比较。评估了个体检测和检测组合的后验概率。HC2 检测 HPV-DNA 的阳性率为 36.5%，PCR 检测的阳性率为 55.2%。MY09/11 检测到 38%的样本存在 HPV-DNA，GP5+/6+检测到 19.1%，pU1M/2R 检测到 16.4%。pU1M/2R 和 HC2 的一致性最高（总体人群的一致性为 75.31%，k=0.39；细胞学异常的女性为 74.1%，k=0.5）。pU1M/2R 的诊断性能最佳，包括最佳的后验概率和宫颈异常检测（单独或在一组检测中）。pU1M/2R 阳性的女性可能具有更高的疾病进展风险；应评估在宫颈癌筛查计划中联合巴氏涂片检测时的检测性能。
